Hikma Pharmaceuticals has agreed to acquire the assets of Bedford Laboratories, the US generic injectables business of Boehringer Ingelheim’s Ben Venue Laboratories, in a deal worth up to US$300 M. The acquisition will increase the scale and scope of Hikma’s business in the fast-growing US injectables market. The deal follows the October 2013 announcement that Ben Venue was to cease production altogether at its sterile injectables manufacturing facility in Bedford, Ohio owing to the unfeasible cost of remediating systemic manufacturing challenges.